Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian M Alexander

Showing results (121-130 of 159) with videos related to

Pageof 16
Sort By:
Neuro-Oncology|September 2, 2015
A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningiomaAyal A Aizer, Malak Abedalthagafi, Wenya Linda Bi, et al.
World Neurosurgery|November 25, 2018
Neurosurgical Resection and Stereotactic Radiation Versus Stereotactic Radiation Alone in Patients with a Single or Solitary Brain MetastasisNayan Lamba, Daniel N Cagney, Rachel H Brigell, et al.
The Lancet. Oncology|January 6, 2018
Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working groupBrian M Alexander, Paul D Brown, Manmeet S Ahluwalia, et al.
Neuro-Oncology|June 4, 2014
Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningiomaAyal A Aizer, Nils D Arvold, Paul Catalano, et al.
JCO Precision Oncology|September 11, 2020
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With GlioblastomaBrian M Alexander, Lorenzo Trippa, Sarah Gaffey, et al.
Cancer Discovery|October 31, 2020
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor ResponseMeagan Montesion, Karthikeyan Murugesan, Dexter X Jin, et al.
Oncotarget|January 23, 2015
Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningiomaZiming Du, Malak Abedalthagafi, Ayal A Aizer, et al.
Plos One|November 18, 2017
Radiographic prediction of meningioma grade by semantic and radiomic featuresThibaud P Coroller, Wenya Linda Bi, Elizabeth Huynh, et al.
Neuro-Oncology|February 24, 2016
A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapyEudocia Q Lee, Alona Muzikansky, Jan Drappatz, et al.
Oncotarget|September 27, 2014
Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomasJane B Cryan, Sam Haidar, Lori A Ramkissoon, et al.
Pageof 16

Showing results (121-130 of 159) with videos related to

Sort By:
Pageof 16
Neuro-Oncology|September 2, 2015
A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningiomaAyal A Aizer, Malak Abedalthagafi, Wenya Linda Bi, et al.
World Neurosurgery|November 25, 2018
Neurosurgical Resection and Stereotactic Radiation Versus Stereotactic Radiation Alone in Patients with a Single or Solitary Brain MetastasisNayan Lamba, Daniel N Cagney, Rachel H Brigell, et al.
The Lancet. Oncology|January 6, 2018
Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working groupBrian M Alexander, Paul D Brown, Manmeet S Ahluwalia, et al.
Neuro-Oncology|June 4, 2014
Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningiomaAyal A Aizer, Nils D Arvold, Paul Catalano, et al.
JCO Precision Oncology|September 11, 2020
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With GlioblastomaBrian M Alexander, Lorenzo Trippa, Sarah Gaffey, et al.
Cancer Discovery|October 31, 2020
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor ResponseMeagan Montesion, Karthikeyan Murugesan, Dexter X Jin, et al.
Oncotarget|January 23, 2015
Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningiomaZiming Du, Malak Abedalthagafi, Ayal A Aizer, et al.
Plos One|November 18, 2017
Radiographic prediction of meningioma grade by semantic and radiomic featuresThibaud P Coroller, Wenya Linda Bi, Elizabeth Huynh, et al.
Neuro-Oncology|February 24, 2016
A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapyEudocia Q Lee, Alona Muzikansky, Jan Drappatz, et al.
Oncotarget|September 27, 2014
Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomasJane B Cryan, Sam Haidar, Lori A Ramkissoon, et al.
Pageof 16